AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

National Survey on Hypertension in Cardiologic Private Practice

Completed

Conditions: Hypertension

First Posted Date: 2008-06-11

Last Posted Date: 2009-08-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 1800

Registration Number: NCT00695175

Locations: 🇫🇷
Research Site, Yvetot, France

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid

Phase 1

Completed

Conditions: Alzheimer´s Disease

Interventions: Drug: Radioligand (11C)AZD2995
Drug: Radioligand (11C)AZD2184

First Posted Date: 2008-06-06

Last Posted Date: 2009-01-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 13

Registration Number: NCT00692705

Locations: 🇸🇪
Research Site, Stockholm, Sweden

Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy

Completed

Conditions: Prostate Cancer

First Posted Date: 2008-06-06

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 1646

Registration Number: NCT00692874

Locations: 🇭🇺
Research Site, Zalaegerszeg, Hungary

Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment

Completed

Conditions: Schizophrenia
Bipolar Disorder

First Posted Date: 2008-06-06

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 250

Registration Number: NCT00692133

Locations: 🇪🇸
Research Site, Tarragona, Spain

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

Phase 1

Completed

Conditions: Capsaicin Evoked Pain
Heat Sensitivity

Interventions: Drug: AZD1386
Drug: Placebo

First Posted Date: 2008-06-06

Last Posted Date: 2008-06-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 36

Registration Number: NCT00692146

Drug Interaction Study Between AZD3480 and Cytochrome P450

Phase 1

Completed

Conditions: Metabolism
Alzheimer's Disease

Interventions: Drug: Placebo
Drug: AZD3480
Drug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)

First Posted Date: 2008-06-06

Last Posted Date: 2008-11-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT00692510

Locations: 🇸🇪
Research Site, Uppsala, Sweden

Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704

Phase 1

Completed

Conditions: Pain

Interventions: Drug: AZD1704

First Posted Date: 2008-06-06

Last Posted Date: 2008-06-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 80

Registration Number: NCT00692042

Locations: 🇬🇧
Reserach Site, Macclesfield, Cheshire, United Kingdom

Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2008-06-06

Last Posted Date: 2012-06-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 1510

Registration Number: NCT00692289

Locations: 🇭🇺
Research Site, Zalaegerszeg, Hungary

Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2

Completed

Conditions: Upper-GI Symptoms

First Posted Date: 2008-06-05

Last Posted Date: 2009-01-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 850

Registration Number: NCT00691743

Locations: 🇬🇷
Research Site, Xania, Greece

Predictors of Recurrence in Bipolar Disorder in Spain

Completed

Conditions: Bipolar Disorder

First Posted Date: 2008-06-05

Last Posted Date: 2020-01-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 595

Registration Number: NCT00690859

Locations: 🇪🇸
Research Site, Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy